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Introduction
The t(6;9)(p22;q34), frequently reported with a breakpoint
in 6p23 but now known to involve the DEK gene mapping to
6p22.3, is a rare translocation, estimated to occur in 1-2% of
cases of childhood acute myeloid leukemia (AML).1 The
translocation was first identified in 1976, and the first pedi-
atric patient was described in 1982.2,3 The World Health
Organization (WHO) classification of myeloid neoplasms and
acute leukemia from 2008 listed the t(6;9)(p22;q34) as a dis-
tinct entity.4 However, our current knowledge of
t(6;9)(p22;q34) in AML is drawn from relatively small series of
patients, predominantly adults, associating t(6;9) with young
age at onset and a poor outcome.1,5-7 Typically, the t(6;9) pres-
ents as de novo AML, morphologically associated with French-
American-British (FAB) type M2, bone marrow basophilia,
Auer rods, and dysplasia.1,5,7,8 The translocation is primarily
the sole cytogenetic abnormality (80%); among the 20% of
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Acute myeloid leukemia with t(6;9)(p22;q34) is listed as a distinct entity in the 2008 World Health Organization clas-
sification, but little is known about the clinical implications of t(6;9)-positive myeloid leukemia in children. This inter-
national multicenter study presents the clinical and genetic characteristics of 62 pediatric patients with t(6;9)/DEK-
NUP214-rearranged myeloid leukemia; 54 diagnosed as having acute myeloid leukemia, representing <1% of all
childhood acute myeloid leukemia, and eight as having myelodysplastic syndrome. The t(6;9)/DEK-NUP214 was
associated with relatively late onset (median age 10.4 years), male predominance (sex ratio 1.7), French-American-
British M2 classification (54%), myelodysplasia (100%), and FLT3-ITD (42%). Outcome was substantially better
than previously reported with a 5-year event-free survival of 32%, 5-year overall survival of 53%, and a 5-year cumu-
lative incidence of relapse of 57%. Hematopoietic stem cell transplantation in first complete remission improved the
5-year event-free survival compared with chemotherapy alone (68% versus 18%; P<0.01) but not the overall survival
(68% versus 54%; P=0.48). The presence of FLT3-ITD had a non-significant negative effect on 5-year overall survival
compared with non-mutated cases (22% versus 62%; P=0.13). Gene expression profiling showed a unique signature
characterized by significantly higher expression of EYA3, SESN1, PRDM2/RIZ, and HIST2H4 genes. In conclusion,
t(6;9)/DEK-NUP214 represents a unique subtype of acute myeloid leukemia with a high risk of relapse, high frequen-
cy of FLT3-ITD, and a specific gene expression signature.
t(6;9)(p22;q34)/DEK-NUP214-rearranged pediatric myeloid leukemia:
an international study of 62 patients
Julie Damgaard Sandahl,1 Eva A. Coenen,2 Erik Forestier,3 Jochen Harbott,4 Bertil Johansson,5 Gitte Kerndrup,6
Souichi Adachi,7 Anne Auvrignon,8 H. Berna Beverloo,9,10 Jean-Michel Cayuela,11,12 Lucy Chilton,13 Maarten Fornerod,2,14
Valérie de Haas,15 Christine J. Harrison,13 Hiroto Inaba,16 Gertjan J.L. Kaspers,15,17 Der-Cherng Liang,18 Franco Locatelli,19
Riccardo Masetti,20 Christine Perot,21 Susana C. Raimondi,16 Katarina Reinhardt,22 Daisuke Tomizawa,23
Nils von Neuhoff,24 Marco Zecca,25 C. Michel Zwaan,2 Marry M. van den Heuvel-Eibrink,2 and Henrik Hasle1
1Department of Pediatrics, Aarhus University Hospital Skejby, Denmark; 2Department of Pediatric Oncology/Hematology, Erasmus
MC-Sophia Children’s Hospital, Rotterdam, the Netherlands; 3Department of Medical Biosciences, Genetics, Umeå University
Hospital, Sweden; 4Department of Pediatric Hematology/Oncology, Justus-Liebig-University, Giessen, Germany; 5Department of
Clinical Genetics, University and Regional Laboratories Region Skåne, Lund, and Division of Clinical Genetics, Department of
Laboratory Medicine, Lund University, Sweden; 6Department of Pathology, Vejle Hospital, Denmark; 7Human Health Sciences, Kyoto
University, Japan; 8French Leucémie Aique Myeloide Enfant, Hôpital Trousseau, Paris, France; 9Department of Clinical Genetics,
Erasmus Medical Center, Rotterdam, the Netherlands; 10Dutch Childhood Oncology Group, Dutch Working Group on Hemato-
Oncologic Genome Diagnostics, The Hague, the Netherlands; 11Laboratoire d'hématologie, Hôpital Saint-Louis, Paris, France; 12Saint
Louis Institute Paris Diderot, France; 13Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK;
14Department of Biochemistry Medical Genetics Cluster, Erasmus University Medical Center, Rotterdam, the Netherlands; 15Dutch
Childhood Oncology Group, The Hague, the Netherlands; 16Department of Oncology and Pathology, St. Jude Children’s Research
Hospital, Memphis, TN, USA; 17Pediatric Oncology/Hematology, VU University Medical Center, Amsterdam, the Netherlands;
18Department of Pediatrics, Mackay Memorial Hospital, Taipei, Taiwan; 19Department of Pediatric Hematology and Oncology, IRCCS,
Ospedale Bambino Gesù, Rome, and University of Pavia, Italy; 20Oncologia ed Ematologia Pediatrica, Ospedale Sant'Orsola
Malpighi, Università di Bologna, Italy; 21Unité de Cytogénétique Onco-hématologique, Hôpital Saint-Antoine, Paris, France; 22Pediatric
Hematology/Oncology, AML-BFM Group, Germany; 23Department of Pediatrics, Tokyo Medical and Dental University, Japan;
24Institute of Cell and Molecular Pathology, Hannover Medical School, Germany; and 25Pediatric Hematology/Oncology, Fondazione
IRCCS Policlinico “San Matteo”, Pavia, Italy
ABSTRACT
patients with additional secondary changes, gains of chro-
mosomes 8 and 13 are most frequent.1,8,9 Internal tandem
duplication (ITD) in the FMS-related tyrosine kinase 3
(FLT3) gene occurs in 20-30% of de novoAML in adults and
in approximately 10% of childhood AML but in up to
70% of t(6;9)-positive cases.1,8,10,11 The clinical outcome is
poor, with 5-year overall survival rates of 28% reported in
children and 9% in adults.1,5-7 Recent smaller studies,
including both adult and pediatric patients, have shown
that treatment with early allogeneic hematopoietic stem
cell transplantation (HSCT) in first complete remission
may improve the outcome.1,12,13
The t(6;9) results in a fusion of the 5’ part of the DEK
gene at 6p22.3 and the 3’ part of the NUP214 gene, for-
merly known as CAN, located at 9q34, forming the
chimeric DEK-NUP214 gene.14 The DEK-NUP214 protein
has been reported to enhance protein synthesis in cells of
the myeloid lineage but is unable to block differentia-
tion.15,16 The leukemogenic potential of the fusion protein
is restricted to a very small subpopulation of hematopoi-
etic stem cells.17
The characteristics of t(6;9)/DEK-NUP214 AML have so
far not been separately described in pediatric patients and
the prognostic impact in pediatric AML is unclear.1,12,13,18
The aims of this study were to characterize the clinical,
genetic and morphological features of t(6;9)-positive child-
hood myeloid neoplasms in the largest series so far; to
evaluate outcome and to identify genes potentially
involved in leukemogenesis of t(6;9) using gene expression
profiling.
Methods
Patients
The inclusion criteria comprised age between 0-18 years and a
diagnosis of de novo AML or myelodysplastic syndrome (MDS)
with t(6;9)/DEK-NUP214 made between 1 January, 1993 and 31
December, 2011.
The study was conducted within the International Berlin-
Frankfurt-Munster study group cooperation and 24 study groups
and treatment centers participated, providing background data for
frequency analysis and submitting clinical and genetic data on 62
patients. In addition, the study groups contributed smears, bone
marrow biopsies, and material for gene expression analysis. The
nomenclature was reviewed following the International System
for Human Cytogenetic Nomenclature 200919 by three of the co-
authors (JH, BJ, and EF). Available diagnostic smears and bone
marrow biopsies were reviewed by co-author GK.
Patients were treated according to national AML trials, and the
treatment protocols were approved by local ethical committees in
compliance with national regulations.
Gene expression profiling and quantitative real time
polymerase chain reaction analysis
Gene expression profiling was performed on 297 pediatric AML
patients’ samples of which eight were t(6;9)-positive. The gene
expression profiling data on the full cohort have already been pub-
lished but an individual analysis of t(6;9)/DEK-NUP214 was not
performed.20 Original data are available in the Gene Expression
Omnibus repository (http://www.ncbi.nlm.nih.gov/geo; accession
GSE17855). The gene expression profiles of t(6;9)-positive cases
were compared with those of other representative pediatric AML
samples.20 Four top scoring, differentially expressed genes were
selected for mRNA expression validation by quantitative real time
polymerase chain reaction (RT-qPCR) analysis based on statistical
significance, occurrence of multiple probes in the top-list, and log-
fold change, combined with potential biological relevance; EYA3
(eyes absent homolog 3, Drosophila), SESN1 (sestrin 1),
PRDM2/RIZ (PR domain containing 2, with ZNF domain), and
HIST2H4 (histone cluster 2, H4). RT-qPCR was performed on
t(6;9)/DEK-NUP214-positive samples from 17 patients and one
cell line (FKH-1) and compared with AML without t(6;9)/DEK-
NUP214 (31 samples from patients and 13 cell lines) using the ABI
PRISM 7900HT sequence detector (Applied Biosystems, Foster
City, CA, USA). Primer sequences are listed in Online
Supplementary Table S1.
Statistical analyses
The Kaplan-Meier method was used to estimate the 5-year
probabilities of overall survival and event-free survival. The 5-year
cumulative incidence of relapse was calculated by the method of
Kalbfleisch and Prentice.21 The median time to HSCT in first com-
plete remission was 150 days, with 98 days as minimum. Patients
with an event within 150 days of treatment were excluded from
the analysis comparing the effect of HSCT in first complete remis-
sion with that of conventional chemotherapy alone. Statistical
analyses were conducted using SPSS for Mac, version 20 (SPSS
Science, Chicago, IL, USA).
Gene expression profiling data were acquired using Expresso
(Bioconductor package Affy). Probe-set intensities were normal-
ized using variance stabilization normalization (Bioconductor
package VSN) in the statistical data analysis environment R, ver-
sion 2.11.22 An empirical Bayes linear regression model was used
to compare the signatures for the t(6;9)-positive cases with those
of the other AML cases.23 Moderated T-statistics P-values were
corrected for multiple testing using the false discovery rate
method, as defined by Benjamini and Hochberg.24
Details of the methods and primer sequences are provided in
the Online Supplementary Appendix.
Results
Of the 24 study groups/centers that participated in the
study, 15 provided clinical and cytogenetic data and sam-
ples for morphologic and gene expression analyses. The
remaining nine study groups reported no patients with
t(6;9)/DEK-NUP214. Data on 70 children were submitted.
Eight patients were excluded; four were diagnosed before
1993 and four had incomplete karyotype with unknown
t(6;9) breakpoints and no proof of the DEK-NUP214 gene
fusion. Accordingly 62 patients fulfilled the inclusion crite-
ria. One study group did not report frequency background
data and was not included in the frequency analysis, and
since this was an AML estimate, EWOG-MDS was not
included either. Thus 22 of the 24 study groups/centers
reported altogether 7363 childhood AML cases with com-
plete cytogenetic data, 45 of which had t(6;9)/DEK-
NUP214, corresponding to a frequency of 0.6% of pedi-
atric AML.
Of the 62 t(6;9)/DEK-NUP214myeloid malignancies, 54
were diagnosed as de novo AML and eight as MDS. The
clinical, morphological, and genetic characteristics of the
cohort are listed in Table 1. The AML and MDS groups
were comparable except for age; children diagnosed with
MDS were younger (median age 7.4 years versus 11.4
years; P<0.05). This notwithstanding, considering all other
similarities, we combined t(6;9)/DEK-NUP214 AML and
MDS cases into one entity. 
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Morphology
The majority of t(6;9) cases were categorized as FAB
type M2 (54%) or FAB type M4 (26%) (Table 1). Peripheral
blood and bone marrow smears from 11 and 15 cases,
respectively, of which two were MDS cases, were evalu-
able for review along with 7 bone marrow biopsies.
Dysplasia was defined according to EWOG-MDS guide-
lines.25 All bone marrow biopsies displayed mild to mod-
erate bilinear dysplasia. Basophils were present in the
bone marrow from five (33%) of the reviewed cases, but
did not exceed 2% in any case. Data on basophils were
available for 16 cases without central review; five had 0.5-
2% basophils in the bone marrow while no basophils
were reported in the remaining 11 patients. No Auer rods
were identified in the material reviewed. Among the cases
not centrally reviewed, Auer rods were reported in ten of
28 (36%) cases. The morphological characteristics found
by the central review are shown in Online Supplementary
Figure S1.
Cytogenetics
Successful cytogenetic results were available in 58 of the
cases; in the remaining four, the DEK-NUP214 gene fusion
was detected by RT-PCR or fluorescence in situ hybridiza-
tion. Among the 58 cytogenetically informative cases,
t(6;9)(p22;q34) was the sole cytogenetic abnormality in 47
(81%) while 11 (19%) had additional aberrations, includ-
ing loss of chromosome Y in three boys and trisomy 8 and
trisomy 13 each present in three cases, either alone or
combined. The karyotypes with additional aberrations are
listed in Online Supplementary Table S2.
Outcome and prognostic factors
Outcome data were available for all 62 children. There
were no differences in overall and event-free survival
between children diagnosed with AML or with MDS;
however, due to the heterogeneity of the treatment strate-
gies for AML and MDS, the following survival estimates
are based on AML cases only (Table 2). The median fol-
low-up for the survivors was 4.7 years (range, 0.2 – 17.1).
Fifty of the children (93%) achieved a complete remission
and 25 (46%) experienced relapse. The latest event
occurred 41 months after diagnosis. The 5-year event-free
survival rate was 32% (±14%), the 5-year overall survival
rate was 53% (±14%), and the 5-year cumulative inci-
dence of relapse was 57% (±14%).
Sex, age, and white blood cell count were not prognostic
factors for event-free survival, overall survival or cumula-
tive incidence of relapse (Table 2). Patients with FAB M4
had a worse outcome than patients with other FAB sub-
types, with a 5-year event-free survival of 9% versus 40%
(P=0.04) and 5-year cumulative incidence of relapse of
91% versus 49% (P<0.01) respectively, but they were over-
represented among the FLT3-ITD-positive cases (P=0.02).
In total, FLT3-ITD status was known in 33 (53%) cases:
14 (42%) were FLT3-ITD-positive and 19 (58%) were
FLT3-ITD-negative (wild-type and one tyrosine kinase
domain point mutation). The allelic ratio of FLT3-ITD was
not available. Among the 29 FLT3 informative AML cases
included in the survival analysis, presence of FLT3-ITD
had a non-significant negative effect on outcome com-
pared with absence of FLT3-ITD (Table 2 and Online
Supplementary Figure S2C,D). 
In the evaluation of HSCT, MDS patients were excluded
along with cases with events earlier than 150 days to cor-
rect for time to transplantation. Eighteen AML patients
were transplanted in first complete remission and 14 after
relapse. The characteristics of the HSCT are presented in
Online Supplementary Table S3. HSCT in first complete
remission significantly improved the 5-year event-free sur-
vival compared with treatment with chemotherapy alone
in first complete remission: 68% versus 18% (P<0.01), but
did not improve the overall survival rate (68% versus 54%;
P=0.48; Online Supplementary Figure S2A,B). A total of five
patients died after HSCT; one from progressive disease
following relapse and four from procedure-related toxicity
(two infections and two cases of multiorgan failure).
FLT3-ITD status was known for 24 of the 48 cases
included in the HSCT analysis. Twelve were FLT3-ITD-
positive, of which eight received chemotherapy only and
four had HSCT in first complete remission. None of the
eight patients treated with conventional chemotherapy
survived without an event, whereas there were no events
among the four ITD-positive patients treated with HSCT
in first complete remission. Twelve patients were FLT3-
t(6;9)(p22;q34) pediatric myeloid leukemia
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Table 1.  Characteristics of patients with t(6;9)(p22;q34)/DEK-NUP214-
rearranged myeloid  leukemia.
AML MDS Total
N =54 N =8   N=62
Boys 34 (63%) 5 (63%) 39 (63%)
Median age in years (range) 11.4*(3.4-17.6) 7.4 *( 4.1-13.2) 10.4 (3.4-17.6)   
0-1 year 0 0 0
2-9 years 21 (39%) 5 (63 %) 26 (42%)
10-18 years 33 (61%) 3 (37%) 36 (58%)
Hematologic parameters median (range)
WBC (x109/L) (N=58) 16.4 (0.2-191.0) 11.8 (1.9-29.0) 16.0 (0.2-191.0)
Hb (g/dL) (N=56) 8.2 (1.9-12.2) 7.3 (4.0-12.3) 8.0 (1.9-12.3)
Platelets (x109/L) (N=48) 63.0 (6.0-235.0) 76.5 (15.0-92.0) 70.5 (6.0-235.0)
PB blasts (%) (N=50) 36 (0-99)** 9 (0-16)** 31 (0-99)
BM blasts (%) (N=53) 60 (14-95)** 10 (5-19)** 55 (5-95)
FAB
M0 1 (2%) 1
M1 4 (7%) 4
M2 29 (54%) 29
M4 14 (26%) 14
M5 1 (2%) 1
Unclassifiable 5 (9%) 5
MDS 8 8
Cytogenetics
t(6;9) sole abnormality 40 (74%) 7 (88%) 47 (81%)
Additional aberrations 10 (19%) 1 (13%) 11 (19%)
FISH or PCR only 4 (7%) 0 4 (6%)
HSCT 32 (59%) 7 (88%) 39 (63%)
First complete remission 18 (55%) 3 (43%) 21 (54%)
Residual disease 0 3 (43%) 3 (8%)
After relapse 14 (45%) 1 (14%) 15 (38%)
Complete remission 50 (93%) 5 (63%) 55 (89%)
No event 20 (37%) 5 (63%) 25 (40%)
Relapse 25 (46%) 3 (38%) 28 (45%)
Survival (SE)
5-year EFS 32% (7) 55% (20) 35% (7)
5-year OS 53% (7) 86% (13) 57% (7)
5-year CIR 57 % (7) 45% (20) 56% (7)
* P< 0.05,  ** P< 0.01
AML: acute myeloid leukemia; MDS: myelodysplastic syndrome; WBC: white blood cell count; Hb:
hemoglobin; PB: peripheral blood; BM: bone marrow;  FAB: French-American-British subtype; FISH:
fluorescence in situ hybridization, PCR: polymerase chain reaction; HSCT: hematopoietic stem-cell
transplantation; EFS: event-free survival; OS: overall survival; CIR: cumulative incidence of relapse
ITD-negative; three were transplanted in first complete
remission, of whom one relapsed and nine received
chemotherapy alone in first complete remission, of whom
six relapsed.
Multivariate analysis was used to assess survival param-
eters of patients with FLT3-ITD treated with HSCT in first
complete remission. The limited number of patients and
information on FLT3-ITD status necessitated a strict selec-
tion of variables that could be included in the Cox model.
We therefore performed stepwise exclusion and the best
possible model was adjusted for HSCT and FLT3-ITD.
FAB type M4 was overrepresented among FLT3-ITD-pos-
itive cases and was not an independent prognostic factor;
thus, FAB type M4 was excluded from further analysis.
Treatment with HSCT in first complete remission was
independently associated with higher event-free survival
(P=0.03) whereas FLT3-ITD mutation was not an inde-
pendent prognostic factor (Online Supplementary Table S4).
Gene expression profiling
The supervised analysis of gene expression levels of
DEK-NUP214-positive samples versus other pediatric
AML samples resulted in a top-table of 180 distinctive
probe-sets with a false discovery rate-adjusted P value
<0.05. The t(6;9)/DEK-NUP214 cases were characterized
by high expression of four genes in particular: HIST2H4
(log fold-change 2.75; adjusted P value of 8.17x10-15);
PRDM2/RIZ (log fold-change 1.5, adjusted P value 2.86
x10-9), represented by four probe-sets in the top-table,
SESN1 (log fold-change 1.24; adjusted P value 6.30 x10-5),
and EYA-3, represented twice with log fold-changes 0.46
and 0.33 (adjusted P value 1.75 x10-10). mRNA expression
levels determined by RT-qPCR correlated well with the
expression profiles derived from gene expression profiling.
The expression of these four genes among cytogenetic
subgroups of pediatric AML, determined by both gene
expression profiling and RT-qPCR, and their correlations
are shown in Figure 1. The unsupervised analysis is pre-
sented in Online Supplementary Figure S3, revealing that the
t(6;9)/DEK-NUP214 cases did not cluster in an unsuper-
vised manner.
In the top-table, 158 probe sets represented up-regulated
genes, including several HOXA and HOXB genes;
(HOXB2, B3, B4, B5, B6, B8, and B9). The high expression
levels of the HOXA and the HOXB genes were validated
in a previous study.26
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Table 2.  Overall survival, event-free survival, and cumulative incidence of relapse for children with t(6;9)(p22;q34)/DEK-NUP214-rearranged AML
(N=54).
5-year OS % (SE) P-log rank 5-year EFS % (SE) P-log rank 5-year CIR % (SE)  P-Gray
Year of diagnosis
1993-1999 (N=18) 44 (12) 0.75 17 (9) 0.72 66 (12) 0.48
2000-2006 (N=18) 61 (12) 44 (12) 52 (12)
2007-2012 (N=18) 55 (14) 34 (14) 53 (15)
Sex
Female (N=20) 51 (13) 0.84 33 (12) 0.90 62 (12) 0.35
Male (N=34) 53 (9) 31 (8) 54 (9)
Age groups
2-9 (N=21) 64 (11) 0.29 32 (10) 0.83 50 (11) 0.34
>10 (N=33) 44 (10) 33 (9) 62 (10)
WBC count
WBC <20x109/L (N=29) 56 (10) 0.19 35 (10) 0.66 58 (10) 0.51
WBC 20-99x109/L (N=20) 58 (11) 32 (11) 61 (12)
WBC ≥100x109/L (N=4) 0 0 no relapse
FAB classification*
M0 (N=1) no events 0.47 no events 0.36 no relapse 0.55
M1 (N=4) 67 (27) 50 (25) 25 (22)
M2 (N=29) 56 (10) 35 (10) 54 (10)
M4 (N=14) 39 (14) 0.17 9 (8) 0.04 91 (8) <0.01
M5 (N=1) no events no events no relapse
Unclassifiable (N=5) 40 (22) 40 (22) no relapse
Cytogenetics
t(6;9)(p22;q34), sole abnormality (N=40) 50 (8) 0.81 28 (8) 0.57 60 (8) 0.32
Additional aberrations (N=10) 55 (17) 37 (19) 48 (21)
FLT3-ITD**
Positive (N=14) 22 (14) 0.13 17 (14) 0.29 75 (16) 0.10
Negative (N=15) 62 (13) 31 (14) 46 (16)
HSCT in first complete remission***
Yes (N=18) 68 (12) 0.48 68 (12) <0.01 13 (9) <0.01
No (N=30) 54 (10) 18 (7) 81 (8)
*The log-rank values are based on a comparison between all FAB subtypes. Only FAB M4 differed from the others, hence the additional analysis of FAB M4 vs. all others. **Four
FLT3-ITD-positive patients were treated with HSCT in first complete remission with no events; all eight FLT3–ITD-positive patients not treated with HSCT relapsed.*** The analysis
of survival is based on patients with EFS >150 days, no patients were censored after HSCT.  WBC: white blood cell count;  FAB: French-American-British subtype;  HSCT: hematopoietic
stem-cell transplantation; EFS: event-free survival; OS: overall survival; CIR: cumulative incidence of relapse.
t(6;9)(p22;q34) pediatric myeloid leukemia
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Figure 1. The expression of HIST2H4, EYA3, SESN1,
and PRDM2/RIZ among cytogenetic subgroups of
pediatric AML as determined by gene expression
profiling (A, D, G and J); RT-qPCR (B, E, H, K and M)
and their correlation (C, F, I, L, and N). For the
PRDM2/RIZ gene, the expression levels of both the
RIZ-PR and RIZ-CR transcripts were measured by
RT-qPCR. CN: cytogenetically normal; NPB: normal
peripheral blood; NBM: normal bone marrow.
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Discussion
The t(6;9)/DEK-NUP214-rearranged cases in this cohort
represented less than 1% of childhood AML with avail-
able cytogenetics based on the data collected from 22
major study groups/centers - a frequency lower than pre-
viously reported.1,5 The translocation is easily detected by
conventional karyotyping and the risk of undetected cases
is considered minimal. An explanation for the low fre-
quency could be the inclusion in the denominator of AML
children from the study groups who did not report t(6;9)
cases in the frequency analysis.
The median age was 10.4 years and no patient was diag-
nosed before 3 years of age. The age distribution is very
different from the general age distribution in AML in
which approximately 30% of patients are less than 3 years
of age at diagnosis.27 To our knowledge, no t(6;9)-positive
cases have been reported in children below 3 years of age9,
which strengthens our finding. The male dominance in
this study has also been observed in adult series of
t(6;9).1,5,7
As in most previous adult studies on t(6;9) AML, the
FAB subtypes FAB M2 and FAB M4 were most com-
mon,1,5,6,28 together constituting 80% of all cases in the
present cohort (Table 1). The present study suggests that
there are differences in the morphology among pediatric
and adult t(6;9) myeloid malignancies. Basophilia seems
less common in children than in adults along with a signif-
icant but milder degree of dysplasia in childhood myeloid
malignancies.1,7,28 Pseudo-Pelger Huët cells were found in
all 15 patients reviewed. This observation is in contrast to
that in pediatric MDS, in which such cells are only rarely
found (GK, personal communication 2012). The similar clini-
cal and morphological characteristics between t(6;9)-posi-
tive AML and MDS found in this large pediatric series sug-
gest that t(6;9)/DEK-NUP214, like t(8;21)/RUNX1-
RUNX1T1 and inv(16)(p13q22) or t(16;16)(p13;q22)/
CBFB-MYH11, should be classified as AML regardless of
the blast count.
FLT3-ITD mutations were present in 42% of the present
cohort, which is less than reported in the literature,1,6 and
had a negative impact on outcome (Table 2), though this
did not reach statistical significance. The COG study on
t(6;9) AML reported no significant impact of FLT3-ITD on
outcome (overall survival rates for FLT3-ITD-positive and
-negative cases were 39% versus 20%, respectively).
However, the ITD-positive patients in the COG study
were allocated to a high-risk treatment protocol including
HSCT while ITD-negative cases were assigned to an inter-
mediate-risk protocol without transplantation,29 which
might have influenced the outcome. In the present study,
all eight FLT3-ITD-positive patients treated without
HSCT in first complete remission experienced a relapse
and subsequently only two survived (with follow-ups of
12 and 13 months), whereas the four FLT3-ITD-positive
patients treated with HSCT were alive without disease in
first complete remission at follow-up. Six of the nine ITD-
negative patients, treated with chemotherapy in first com-
plete remission, relapsed. We found a significant improve-
ment of event-free survival resulting from treatment with
HSCT in first complete remission compared with treat-
ment with chemotherapy only, but this did not translate
into superior overall survival (Table 2 and Online
Supplementary Table S4), suggesting a high salvage rate.
Only St. Jude reported t(6;9) as a treatment-stratifying
aberration in the AML02 and 08 protocols relevant for two
patients included in this study and allocated to the high-
risk arm including HSCT. It should be emphasized that
retrospectively collected data have serious limitations
since the factors for allocating patients to HSCT, such as
co-morbidity, individual assessment of the treating physi-
cian, and availability of donor, remain unknown and this
weakness must be taken into account when evaluating the
value of HSCT. We have statistically tried to overcome
some of the obstacles, such as disease stage, by only eval-
uating HSCT in first complete remission and corrected for
time to transplantation. Parameters important for the out-
come of HSCT, such as donor characteristics, and HLA
match are given in Online Supplementary Table S3. The
numbers are small and considering the above-mentioned
limitations, our results are in accordance with those of
other small series.12,13 Notably, 14 children were transplant-
ed after relapse and it is possible that a potential beneficial
effect of HSCT after relapse is reflected in the high salvage
rate. HSCT seems beneficial in patients with t(6;9)/DEK-
NUP214 and in particular for patients with FLT3-ITD.
We identified a unique gene expression signature with,
among others, high expression of HIST2H4, PRDM2/RIZ,
EYA3 and SESN1 in addition to HOXA and HOXB gene
overexpression being characteristic of DEK-NUP214-posi-
tive cases, as it is for AML with NPM1-mutations,
NUP98-NSD1-rearrangements and partial tandem dupli-
cations of the MLL gene, suggesting a common pathway
of leukemogenesis in these cases. The overexpression of
HOXA and HOXB genes in DEK-NUP214-positive cases
was previously validated.26 It is noteworthy that both
DEK-NUP214 and NUP98-NSD1 are characterized by
high HOXA and HOXB gene expression since these two
cytogenetic subgroups share other genetic and clinical
characteristics: a high frequency of FLT3-ITD (40-70% and
>90%, respectively)1,26 and absence of patients below 2
years of age.26 Furthermore, the NUP214 and NUP98 onco-
genic fusion proteins are similar in many respects. First,
both fusions include a nucleoporin-specific FG region
(phenylalanine-glycine repeats), which is associated with
various histone-modifying complexes.30,31 Second, both
fuse to a nuclear factor, mostly but not uniquely a direct
transcription factor.14,31,32 Third, both fusion products are
localized to the nucleus, as opposed to the wild-type
nucleoporins, which are mainly present in the nuclear
pore complex.31,33 It is, therefore, likely that these nucleo-
porin-containing fusion proteins are functionally similar,
acting as aberrant transcriptional modulators.
Within this study, we validated the selective up-regula-
tion of four genes in t(6;9)/DEK-NUP214–positive pedi-
atric cases: HIST2H4, PRDM2/RIZ, EYA3 and SESN1. The
HIST2H4, mapping at 1q21.2, encodes a member of the
histone H4 family but the function of HIST2H4 in leuke-
mogenesis is unknown. The PRDM2 (1p36.21) gene, also
known as RIZ, encodes two proteins: RIZ-PR (RIZ1) and
RIZ-CR (RIZ2). The proteins are identical except that RIZ-
PR has an N-terminal PR domain with methyltransferase
activity that is lacking in RIZ-CR. RIZ-PR has tumor sup-
pressor activity whereas RIZ-CR has been described to
acts as an oncogene.34,35 The probe used in our gene expres-
sion profiling analyses did not distinguish between the
two transcripts. However, in the RT-qPCR validation of
the expression levels, we analyzed the gene expression of
each transcript and found that both the tumor-suppressive
RIZ-PR and the oncogenic RIZ-CRwere up-regulated. The
J.D. Sandahl et al.
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EYA3 gene (1p35.3) encodes a member of the ‘eyes absent’
protein family and is involved in repair and cell survival as
a response to DNA damage in organogenesis.36,37 The
fourth gene SESN1 (6q21) codes for a member of the ses-
trin family and  is known to be a TP53 target.38,39
Considering their known tumor suppressor function, it is
surprising that the SESN1 gene and the RIZ-PR transcript
were both up-regulated in t(6;9)-positive cases.
It is striking that several of the genes found to be signif-
icantly up-regulated in DEK-NUP214–rearranged cases are
known to influence the modeling and function of histones.
Depletion of both DEK and EYA3 causes phosphorylation
of H2Ax (gH2Ax), a subunit of histone H2A,37,40 DEK pro-
tein is able to bind to histones and reduce the levels of his-
tone H3 and H4 acetylation, thus playing an important
role in chromatin modification, histone acetylation and
transcription.40,41 In addition, the most significantly up-reg-
ulated gene was HIST2H4 and the tumor suppressor activ-
ity of RIZ-PR is related to the histone methyl-transferase
activity of the PR domain.42 We hypothesize that specific
histone modifications are key events during leukemogen-
esis, possibly through modulating the epigenetic state of
the cell.
In conclusion, t(6;9)/DEK-NUP214-rearranged cases rep-
resent less than 1% of all childhood AML and are charac-
terized by a late onset, male predominance, FLT3-ITD
mutations, and a high risk of relapse. Nevertheless, a large
proportion of the patients can be cured and HSCT poten-
tially benefits patients with t(6;9) and especially those
with FLT3-ITD. In addition, we identified a unique gene
expression signature including several up-regulated genes
involved in histone modification, and a typical HOXA/B
profile, which may be a target for future therapy.
Acknowledgments
The authors would like to thank all groups involved in retriev-
ing and providing data and material (a list of additional partic-
ipants involved in the study is given in the online supplement).
We especially thank Saint-Louis Hospital’s Tumor Biobank in
Paris (France), the NOPHO Biobank in Uppsala (Sweden), the
St. Jude Children's Research Hospital Tissue Resources
Laboratory in Memphis (USA), and the Giuseppe Basso
Laboratory of Pediatric Oncology, Pediatric Department,
University of Padova, Padova (Italy) for managing patients’
samples, and for valuable samples and smears provided by
regional treatment centers. We thank Susan Arentsen-Peters at
the Laboratory of Pediatric Oncology/Hematology, Erasmus
MC, Rotterdam, NL for technical assistance. This work was
supported by the Danish Childhood Cancer Foundation, the
Swedish Childhood Cancer Foundation, the Dutch Childhood
Oncology Group, a Grant from the Clinical Cancer Research
and Grant-in-Aid for Cancer Research from the Ministry of
Health, Labour and Welfare of Japan.
Authorship and Disclosures
Information on authorship, contributions, and financial & other
disclosures was provided by the authors and is available with the
online version of this article at www.haematologica.org.
t(6;9)(p22;q34) pediatric myeloid leukemia
haematologica | 2014; 99(5) 871
References
1. Slovak ML, Gundacker H, Bloomfield CD,
Dewald G, Appelbaum FR, Larson RA, et al.
A retrospective study of 69 patients with
t(6;9)(p23;q34) AML emphasizes the need
for a prospective, multicenter initiative for
rare 'poor prognosis' myeloid malignancies.
Leukemia. 2006;20(7):1295-7.
2. Rowley JD, Potter D. Chromosomal band-
ing patterns in acute nonlymphocytic
leukemia. Blood. 1976;47(5):705-21.
3. Kaneko Y, Rowley JD, Maurer HS.
Chromosome pattern in childhood acute
nonlymphocytic leukemia (ANLL). Blood.
1982;60(2):389-99.
4. Vardiman JW, Thiele J, Arber DA, Brunning
RD, Borowitz MJ, Porwit A, et al. The 2008
revision of the World Health Organization
(WHO) classification of myeloid neoplasms
and acute leukemia: rationale and important
changes. Blood. 2009;114(5):937-51.
5. Gupta M, Ashok Kumar J, Sitaram U, Neeraj
S, Nancy A, Balasubramanian P, et al. The
t(6;9)(p22;q34) in myeloid neoplasms: a ret-
rospective study of 16 cases. Cancer Genet
Cytogenet. 2010;203(2):297-302.
6. Garcon L, Libura M, Delabesse E, Valensi F,
Asnafi V, Berger C, et al. DEK-CAN molecu-
lar monitoring of myeloid malignancies
could aid therapeutic stratification.
Leukemia. 2005;19(8):1338-44.
7. Alsabeh R, Brynes RK, Slovak ML, Arber
DA. Acute myeloid leukemia with t(6;9)
(p23;q34): association with myelodysplasia,
basophilia, and initial CD34 negative
immunophenotype. Am J Clin Pathol. 1997;
107(4):430-7.
8. Oyarzo MP, Lin P, Glassman A, Bueso-
Ramos CE, Luthra R, Medeiros LJ. Acute
myeloid leukemia with t(6;9)(p23;q34) is
associated with dysplasia and a high fre-
quency of flt3 gene mutations. Am J Clin
Pathol. 2004;122(3):348-58.
9. Mitelman Database of Chromosome
Aberrations and Gene Fusions in Cancer
(2013). Mitelman F, Johansson B and
Mertens F (Eds.), http://cgap.nci.nih.gov/
Chromosomes/Mitelman.
10. Chi Y, Lindgren V, Quigley S, Gaitonde S.
Acute myelogenous leukemia with
t(6;9)(p23;q34) and marrow basophilia: an
overview. Arch Pathol Lab Med. 2008;132
(11):1835-7.
11. Zwaan CM, Meshinchi S, Radich JP,
Veerman AJP, Huismans DR, Munske L, et
al. FLT3 internal tandem duplication in 234
children with acute myeloid leukemia:
prognostic significance and relation to cel-
lular drug resistance. Blood. 2003;102(7):
2387-94.
12. Ishiyama K, Takami A, Kanda Y, Nakao S,
Hidaka M, Maeda T, et al. Allogeneic
hematopoietic stem cell transplantation for
acute myeloid leukemia with t(6;9)(p23;q34)
dramatically improves the patient progno-
sis: a matched-pair analysis. Leukemia.
2012;26(3):461-4.
13. Ishiyama K, Takami A, Kanda Y, Nakao S,
Hidaka M, Maeda T, et al. Prognostic factors
for acute myeloid leukemia patients with
t(6;9)(p23;q34) who underwent an allogene-
ic hematopoietic stem cell transplant.
Leukemia. 2012;26(6):1416-9.
14. Von Lindern M, Fornerod M, Van Baal S,
Jaegle M, De Wit T, Buijs A, et al. The
translocation (6;9), associated with a specific
subtype of acute myeloid leukemia, results
in the fusion of two genes, dek and can, and
the expression of a chimeric, leukemia-spe-
cific dek-can mRNA. Mol Cell Biol.
1992;12(4):1687-97.
15. Ageberg M, Drott K, Olofsson T, Gullberg
U, Lindmark A. Identification of a novel and
myeloid specific role of the leukemia-associ-
ated fusion protein DEK-NUP214 leading to
increased protein synthesis. Genes
Chromosomes and Cancer. 2008;47(4):276-
87.
16. Boer J, Bonten-Surtel J, Grosveld G.
Overexpression of the nucleoporin
CAN/NUP214 induces growth arrest, nucle-
ocytoplasmic transport defects, and apopto-
sis. Mol Cell Biol. 1998;18(3):1236-47.
17. Oancea C, Rüster B, Henschler R, Puccetti E,
Ruthardt M. The t(6;9) associated
DEK/CAN fusion protein targets a popula-
tion of long-term repopulating hematopoiet-
ic stem cells for leukemogenic transforma-
tion. Leukemia. 2010;24(11):1910-9.
18. Harrison CJ, Hills RK, Moorman AV,
Grimwade DJ, Hann I, Webb DK, et al.
Cytogenetics of childhood acute myeloid
leukemia: United Kingdom Medical
Research Council Treatment trials AML 10
and 12. J Clin Oncol. 2010;28(16):2674-81.
19. Shaffer LG, Slovak ML, Campbell LJ. ISCN
(2009): International System of Human
Cytogenetic Nomenclature. Basel S Karger
AG; 2009.
20. Balgobind BV, van den Heuvel-Eibrink MM,
De Menezes RX, Reinhardt D, Hollink IH,
Arentsen-Peters STJCM, et al. Evaluation of
gene expression signatures predictive of
cytogenetic and molecular subtypes of
pediatric acute myeloid leukemia.
Haematologica. 2011;96(2):221-30.
21. Kalbfleisch JD, Prentice RL. The Statistical
Analysis of Failure Time Data (2nd ed).
Hoboken NJ: J. Wiley; 2002.
22. Gautier L, Cope L, Bolstad BM, Irizarry RA.
affy--analysis of Affymetrix GeneChip data
at the probe level. Bioinformatics. 2004;20
(3):307-15.
23. Smyth GK. Linear models and empirical
bayes methods for assessing differential
expression in microarray experiments. Stat
Appl Genet Mol Biol. 2004;3:Article3.
24. Benjamini Y, Hochberg Y. Controlling the
false discovery rate: a practical and powerful
approach to multiple testing. Journal of the
Royal Statistical Society Series B
(Methodological). 1995;57(1):289-300.
25. Cantu Rajnoldi A, Fenu S, Kerndrup G, van
Wering ER, Niemeyer CM, Baumann I.
Evaluation of dysplastic features in
myelodysplastic syndromes: experience
from the morphology group of the European
Working Group of MDS in Childhood
(EWOG-MDS). Ann Hematol. 2005;84(7):
429-33.
26. Hollink IH, van den Heuvel-Eibrink MM,
Arentsen-Peters ST, Pratcorona M, Abbas S,
Kuipers JE, et al. NUP98/NSD1 characterizes
a novel poor prognostic group in acute
myeloid leukemia with a distinct HOX gene
expression pattern. Blood. 2011;118(13):
3645-56.
27. Forestier E, Schmiegelow K. The incidence
peaks of the childhood acute leukemias
reflect specific cytogenetic aberrations. J
Pediatr Hematol Oncol. 2006;28(8):486-95.
28. Pearson MG, Vardiman JW, Le Beau MM.
Increased numbers of marrow basophils
may be associated with a t(6;9) in ANLL.
Am J Hematol. 1985;18(4):393-403.
29. Moraleda PP, Alonzo TA, Gerbing RB,
Raimondi SC, Hirsch BA, Ravindranath Y, et
al. Acute myeloid leukemia with
t(6;9)(p23;q34) is associated with poor out-
come in childhood AML regardless of
FLT3/ITD status, a report from Children’s
Oncology Group. ASH Annual Meeting
Abstracts. 2012;120(21):2541.
30. Bai XT, Gu BW, Yin T, Niu C, Xi XD, Zhang
J, et al. Trans-repressive effect of NUP98-
PMX1 on PMX1-regulated c-FOS gene
through recruitment of histone deacetylase
1 by FG repeats. Cancer Res. 2006;66(9):
4584-90.
31. Kasper LH, Brindle PK, Schnabel CA,
Pritchard CE, Cleary ML, van Deursen JM.
CREB binding protein interacts with nucleo-
porin-specific FG repeats that activate tran-
scription and mediate NUP98-HOXA9
oncogenicity. Mol Cell Biol. 1999;19(1):764-
76.
32. Romana SP, Radford-Weiss I, Ben Abdelali R,
Schluth C, Petit A, Dastugue N, et al. NUP98
rearrangements in hematopoietic malignan-
cies: a study of the Groupe Francophone de
Cytogenetique Hematologique. Leukemia.
2006;20(4):696-706.
33. Fornerod M, Boer J, van Baal S, Jaegle M, von
Lindern M, Murti KG, et al. Relocation of
the carboxyterminal part of CAN from the
nuclear envelope to the nucleus as a result of
leukemia-specific chromosome rearrange-
ments. Oncogene. 1995;10(9): 1739-48.
34. Sun W, Qiao L, Liu Q, Chen L, Ling B,
Sammynaiken R, et al. Anticancer activity of
the PR domain of tumor suppressor RIZ1.
Int J Med Sci. 2011;8(2):161-7.
35. Sasaki O, Meguro K, Tohmiya Y, Funato T,
Shibahara S, Sasaki T. Altered expression of
retinoblastoma protein-interacting zinc fin-
ger gene, RIZ, in human leukaemia. Br J
Haematol. 2002;119(4):940-8.
36. Jemc J, Rebay I. The eyes absent family of
phosphotyrosine phosphatases: properties
and roles in developmental regulation of
transcription. Annu Rev Biochem. 2007;
76:513-38.
37. Cook PJ, Ju BG, Telese F, Wang X, Glass CK,
Rosenfeld MG. Tyrosine dephosphorylation
of H2AX modulates apoptosis and survival
decisions. Nature. 2009;458(7238):591-6.
38. Velasco-Miguel S, Buckbinder L, Jean P,
Gelbert L, Talbott R, Laidlaw J, et al. PA26, a
novel target of the p53 tumor suppressor
and member of the GADD family of DNA
damage and growth arrest inducible genes.
Oncogene. 1999;18(1):127-37.
39. Budanov AV, Karin M. p53 target genes
Sestrin1 and Sestrin2 connect genotoxic
stress and mTOR signaling. Cell.
2008;134(3):451-60. Erratum in Cell. 2009;
136(2):378.
40. Ko SI, Lee IS, Kim JY, Kim SM, Kim DW, Lee
KS, et al. Regulation of histone acetyltrans-
ferase activity of p300 and PCAF by proto-
oncogene protein DEK. FEBS Lett.
2006;580(13):3217-22.
41. Waldmann T, Eckerich C, Baack M, Gruss C.
The ubiquitous chromatin protein DEK
alters the structure of DNA by introducing
positive supercoils. J Biol Chem. 2002;
277(28):24988-94.
42. Derunes C, Briknarova K, Geng L, Li S,
Gessner CR, Hewitt K, et al.
Characterization of the PR domain of RIZ1
histone methyltransferase. Biochem
Biophys Res Commun. 2005;333(3):925-34.
J.D. Sandahl et al.
872 haematologica | 2014; 99(5)
